Madrigal Pharmaceuticals Inc (MDGL)
288.58
-14.09
(-4.66%)
USD |
NASDAQ |
Nov 15, 16:00
297.06
+8.48
(+2.94%)
After-Hours: 20:00
Madrigal Pharmaceuticals Research and Development Expense (TTM): 281.71M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 281.71M |
| June 30, 2024 | 283.92M |
| March 31, 2024 | 281.43M |
| December 31, 2023 | 272.35M |
| September 30, 2023 | 272.45M |
| June 30, 2023 | 269.77M |
| March 31, 2023 | 259.67M |
| December 31, 2022 | 245.44M |
| September 30, 2022 | 227.59M |
| June 30, 2022 | 214.19M |
| March 31, 2022 | 207.32M |
| December 31, 2021 | 205.16M |
| September 30, 2021 | 205.70M |
| June 30, 2021 | 204.12M |
| March 31, 2021 | 197.18M |
| December 31, 2020 | 184.81M |
| September 30, 2020 | 156.29M |
| June 30, 2020 | 122.44M |
| March 31, 2020 | 93.35M |
| December 31, 2019 | 72.32M |
| September 30, 2019 | 56.28M |
| June 30, 2019 | 43.05M |
| March 31, 2019 | 32.56M |
| December 31, 2018 | 25.39M |
| September 30, 2018 | 23.03M |
| Date | Value |
|---|---|
| June 30, 2018 | 23.50M |
| March 31, 2018 | 25.21M |
| December 31, 2017 | 24.39M |
| September 30, 2017 | 23.40M |
| June 30, 2017 | 24.52M |
| March 31, 2017 | 19.80M |
| December 31, 2016 | 15.93M |
| September 30, 2016 | 11.18M |
| June 30, 2016 | 4.060M |
| March 31, 2016 | 18.35M |
| December 31, 2015 | 34.01M |
| September 30, 2015 | 48.89M |
| June 30, 2015 | 64.42M |
| March 31, 2015 | 66.80M |
| December 31, 2014 | 68.20M |
| September 30, 2014 | 72.53M |
| June 30, 2014 | 73.95M |
| March 31, 2014 | 73.06M |
| December 31, 2013 | 71.86M |
| September 30, 2013 | 66.23M |
| June 30, 2013 | 60.35M |
| March 31, 2013 | 53.73M |
| December 31, 2012 | 49.41M |
| September 30, 2012 | 45.92M |
| June 30, 2012 | 44.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
72.32M
Minimum
Dec 2019
283.92M
Maximum
Jun 2024
212.86M
Average
210.76M
Median
Research and Development Expense (TTM) Benchmarks
| Corcept Therapeutics Inc | 231.29M |
| ADMA Biologics Inc | 1.868M |
| 89bio Inc | 267.33M |
| Sarepta Therapeutics Inc | 800.09M |
| Matinas BioPharma Holdings Inc | 13.78M |